Harvard Bioscience 10-Q: Q3 Loss Widens to $2.6M, Cash Falls to $4.9M With Going-Concern Review
HBIO has more than doubled off its 52-week low of $4 on elevated volume (4.1× avg).
Summary
Harvard Bioscience grew Q3 revenue 7.8% to $22.2M but lost $2.6M and burned cash down to $4.9M; management ran a going-concern analysis and concluded no substantial doubt within twelve months, though liquidity conditions are adverse.
Key Events · Earnings and Guidance · HBIO
-
Q3 Revenue Up 7.8%, Loss Widens
Revenue rose to $22.2M from $20.6M, but net loss widened to $2.6M ($0.58 per share) from $1.2M, and nine-month net loss reached $9.0M.
-
Cash Falls to $4.9M
Cash and equivalents dropped from $8.6M at December 31, 2025 to $4.9M at September 30, 2026, with $0.6M used in operating activities over nine months.
-
Going-Concern Review Concluded No Doubt
Management identified adverse liquidity conditions — recurring net losses, negative operating cash flow, declining cash — but concluded they do not raise substantial doubt about continuing as a going concern within twelve months.
-
Debt Covenants and 17.8% Effective Rate
$40M outstanding under the 2025 Loan Agreement; company was in compliance with the $3M minimum liquidity and $6M trailing adjusted EBITDA covenants at September 30, 2026.
Analysis · HBIO · Industrial Applications And Services
Revenue grew 7.8% to $22.2M, yet the company still lost $2.6M in the quarter and $9.0M over nine months, while cash dropped from $8.6M to $4.9M. Management explicitly evaluated going-concern doubt under ASC 205-40 and concluded the adverse liquidity conditions — recurring losses, negative operating cash flow, shrinking cash — do not raise substantial doubt within twelve months. That conclusion rests on covenant compliance and forecasted cash flows, so the margin for error is thin: the 2025 Loan Agreement requires $3M minimum liquidity at all times and $6M trailing adjusted EBITDA, and interest runs at a 17.8% effective rate on $40M of debt. Gross margin also compressed to 55.4% from 58.4% on restructuring charges and unfavorable mix.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HBIO was trading at $9.26 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $42.2M. The 52-week trading range was $4.00 to $9.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.